Skip to main content

Clinical Management

  • 277 Accesses

Abstract

Urine cytology remains an important adjunctive test in the diagnostic armamentarium of the urologist. The clinical scenarios in which urine cytology is performed include the evaluation of hematuria and irritative voiding symptoms, initial work-up for a suspected urothelial malignancy, and surveillance following treatment for urothelial cancer. The work-up for a given cytologic diagnosis may include contrast-enhanced imaging and cystoscopy, depending on the degree of clinical suspicion. Urine cytology may be particularly useful in situations where direct endoscopic visualization can be difficult or impractical, such as in the upper urinary tract or following urinary diversion. The ultimate care of the patient should be individualized based on all available information. Communication between the clinician and cytopathologist is essential in order to optimally utilize urine cytology.

Keywords

  • Hematuria
  • Urothelial carcinoma
  • Transurethral resection of bladder tumor
  • Cystoscopy
  • Radical cystectomy
  • Intravesical chemotherapy
  • Intravesical immunotherapy
  • Fluorescence cystoscopy
  • Narrowband imaging
  • CT urography
  • Urethral recurrence
  • Upper tract urothelial carcinoma

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-88686-8_12
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   54.99
Price excludes VAT (USA)
  • ISBN: 978-3-030-88686-8
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   69.99
Price excludes VAT (USA)

References

  1. Kurtycz DFI, Barkan GA, Pavelec DM, Rosenthal DL, Wojcik EM, VandenBussche CJ, Mangiulli K, Olson MT. Paris interobserver reproducibility study (PIRST). J Am Soc Cytopathol. 2018;7:174–84.

    CrossRef  Google Scholar 

  2. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021–9.

    CrossRef  Google Scholar 

  3. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32:222–9.

    CAS  CrossRef  Google Scholar 

  4. Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33:66.e25–31.

    CrossRef  Google Scholar 

  5. Barocas DA, Boorjian SA, Alvarez RD, Downs TM, Gross CP, Hamilton BD, Kobashi KC, Lipman RR, Lotan Y, Ng CK, Nielsen ME, Peterson AC, Raman JD, Smith-Bindman R, Souter LH. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204:778–86.

    CrossRef  Google Scholar 

  6. Chen H, Liu L, Pambuccian SE, Barkan GA, Quek ML, Wojcik EM. Urine cytology in monitoring recurrence in urothelial carcinoma after radical cystectomy and urinary diversion. Cancer Cytopathol. 2016;124:273–8.

    CrossRef  Google Scholar 

  7. Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S, Bozzini G, Carmignani L. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012;188:2046–54.

    CrossRef  Google Scholar 

  8. Nomani L, Abro S, Quek ML, Barkan GA. Guar bean in urinary cytology: a morphologic pitfall. J Am Soc Cytopathol. 2021;10:41–6.

    CrossRef  Google Scholar 

  9. Mitra AP, Alemozaffar M, Harris BN, Schuckman AK, Skinner EC, Daneshmand S. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Urology. 2014;84:1420–6.

    CrossRef  Google Scholar 

  10. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004;172:1342–7.

    CrossRef  Google Scholar 

  11. Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol. 2007;177:2088–94.

    CrossRef  Google Scholar 

  12. Stein JP, Penson DF, Wu SD, Skinner DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol. 2007;178:756–60.

    CrossRef  Google Scholar 

  13. Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Clinical significance of random bladder biopsy in primary T1 bladder cancer. Mol Clin Oncol. 2018;8:665–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Takamatsu K, Matsumoto K, Kikuchi E, Ogihara K, Hayakawa N, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Asanuma H, Mikami S, Oyama M, Oya M. Can random bladder biopsies be eliminated after bacillus Calmette-Guerin therapy against carcinoma in situ? Int Urol Nephrol. 2021;53:465–9.

    CAS  CrossRef  Google Scholar 

  15. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Drager BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63:4–15.

    CrossRef  Google Scholar 

  16. Bubendorf L, Piaton E. UroVysion(R) multiprobe FISH in the triage of equivocal urinary cytology cases. Ann Pathol. 2012;32:e52–6, 438–43.

    CrossRef  Google Scholar 

  17. Gayed BA, Seideman C, Lotan Y. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013;190:1181–6.

    CAS  CrossRef  Google Scholar 

  18. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101–5.

    CAS  CrossRef  Google Scholar 

  19. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, Brainard JA, Biscotti CV, Jones JS, Tubbs RR. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301.

    CrossRef  Google Scholar 

  20. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013;63:936–40.

    CrossRef  Google Scholar 

  21. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy. Eur Urol. 2019;76:238–43.

    CrossRef  Google Scholar 

  22. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11:589–96.

    CAS  CrossRef  Google Scholar 

  23. Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, Liao JC, Pohar K, Tierney J, Konety B, Blue Light Cystoscopy with Cysview Registry Group. Blue light cystoscopy for the diagnosis of bladder cancer: results from the US prospective multicenter registry. Urol Oncol. 2018;36:361.e1–6.

    CrossRef  Google Scholar 

  24. Herr HW. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. Eur Urol. 2015;67:605–8.

    CrossRef  Google Scholar 

  25. Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015;121:169–78.

    CrossRef  Google Scholar 

  26. Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmstrom PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA – update 2018. Nat Rev Urol. 2019;16:377–86.

    CrossRef  Google Scholar 

  27. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184:1907–13.

    CrossRef  Google Scholar 

  28. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66:863–71.

    CrossRef  Google Scholar 

  29. Doshi CP, Barkan GA, Quek ML. Urothelial carcinoma recurrence in an orthotopic neobladder without urethral or upper urinary tract involvement. Case Rep Urol. 2019;2019:8458706.

    PubMed  PubMed Central  Google Scholar 

  30. Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Adibi M, Amin MB, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner SP. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020;21:776–85.

    CAS  CrossRef  Google Scholar 

  31. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015;29:237–52.

    CrossRef  Google Scholar 

  32. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–30.

    CrossRef  Google Scholar 

  33. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M, European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–53.

    CrossRef  Google Scholar 

  34. Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Bohle A, Colombel M, Palou J. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;192:305–15.

    CrossRef  Google Scholar 

  35. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern California experience. J Urol. 2005;174:93–6.

    CrossRef  Google Scholar 

  36. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004;172:481–4.

    CrossRef  Google Scholar 

  37. Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, Horenblas S, Bex A. Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J Urol. 2013;20:778–84.

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marcus L. Quek .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Quek, M.L. et al. (2022). Clinical Management. In: Wojcik, E.M., Kurtycz, D.F., Rosenthal, D.L. (eds) The Paris System for Reporting Urinary Cytology. Springer, Cham. https://doi.org/10.1007/978-3-030-88686-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-88686-8_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-88685-1

  • Online ISBN: 978-3-030-88686-8

  • eBook Packages: MedicineMedicine (R0)